At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 30, 2026 at 16:01 ET
Praxis Precision Medicines announced FDA acceptance of its NDA for relutrigine, a first-in-class therapy for SCN2A and SCN8A developmental and epileptic encephalopathies, with a PDUFA target action date of September 27, 2026. The filing is supported by strong Phase 2 data showing robust seizure reduction, and the drug has multiple expedited designations including Breakthrough Therapy and Rare Pediatric Disease Designation.
- FDA accepted NDA for relutrigine with priority review and PDUFA date of September 27, 2026
- Relutrigine is first potential disease-modifying therapy for SCN2A/SCN8A DEEs, which currently have no approved targeted treatments
- NDA supported by positive interim results from EMBOLD study, stopped early for efficacy
- Relutrigine has Orphan Drug, Rare Pediatric Disease, and Breakthrough Therapy Designations
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access